Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Inhibrx Biosciences, Inc. (INBX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$80.28-7.47%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INBX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
narrowing EPS losses toward -$6.3 in FY27 | If clinical trials succeed, earnings losses could narrow from -$9.26 to -$6.3 per share by next year. | Improving | EPS losses worsen or remain below -6.3 in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology company, not a proven earnings compounder. The multi-year thesis is in a watch state: clinical progress is visible, but execution and funding risks remain elevated.
The evidence flags valuation as expensive, though its valuation score fell sharply and the overall signal shifted from mildly favorable to mixed. The snapshot does not specify what clinical or commercial expectations are embedded in that valuation, so the expectations gap is unclear.
Near term, the company is likely to remain loss-making: its quarterly net loss increased slightly, and cash declined from the first to the second quarter of 2026. INBRX-106 data showed higher response and longer median progression-free survival than pembrolizumab alone in the reported study, while financing and continued regulatory engagement support development; however, recent performance has lagged its industry cohort and the next report carries elevated miss risk.
The multi-year thesis hinges on whether clinical development, including plans to expand the Phase 2 study and discuss potential registrational trials with the FDA, can build on the reported results. It also depends on managing cash burn and financing needs; in the near term, weakening employment data or weaker results from sector bellwethers could reduce the supportive Healthcare backdrop.
Over the next 1 to 3 years, INBX offers a clinical-progress story with meaningful financing and execution uncertainty, while its valuation is described as expensive. The evidence supports a watch-state thesis, not a settled view. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Inhibrx Biosciences, Inc.'s published investment case. The stated target is no new material litigation filings. |
| Intact |
| new material litigation filed or existing litigation worsens |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
achieving revenue of at least $57 million in FY27 | A primary condition in Inhibrx Biosciences, Inc.'s published investment case. The stated target is revenue >= 57 million USD. | Broken | revenue fails to reach $57 million in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.53 → $-8.94 · observed estimates
$0.06B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-07-25 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-07-26 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-07-27 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-07-28 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-07-29 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-07-30 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-07-31 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-01 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-02 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-03 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-04 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-05 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-06 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-07 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-08 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-09 | $-6.30 | $57,175,000 | 1 / 2 |
| 2026-08-10 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-12 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-13 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-14 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-15 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-16 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-17 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-18 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-19 | $-6.53 | $57,200,000 | 1 / 2 |
| 2026-08-20 | $-7.79 | $57,200,000 | 1 / 2 |
| 2026-08-21 | $-7.79 | $57,200,000 | 1 / 2 |
| 2026-08-22 | $-7.79 | $57,200,000 | 1 / 2 |
| 2026-08-23 | $-7.79 | $57,200,000 | 1 / 2 |
| 2026-08-24 | $-7.79 | $57,200,000 | 1 / 2 |
| 2026-08-25 | $-7.79 | $57,200,000 | 1 / 2 |
| 2026-08-26 | $-8.02 | $46,100,000 | 2 / 2 |
| 2026-08-27 | $-8.02 | $46,100,000 | 2 / 2 |
| 2026-08-28 | $-8.02 | $46,100,000 | 2 / 2 |
| 2026-08-29 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-08-30 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-08-31 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-01 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-02 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-03 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-04 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-05 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-06 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-07 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-08 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-09 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-10 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-11 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-12 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-13 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-14 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-15 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-16 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-17 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-18 | $-8.94 | $36,055,667 | 2 / 3 |
| 2026-09-19 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-20 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-21 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-22 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-23 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-24 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-25 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-26 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-27 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-28 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-29 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-09-30 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-01 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-02 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-03 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-04 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-05 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-06 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-07 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-08 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-09 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-10 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-11 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-12 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-13 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-14 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-15 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-16 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-17 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-18 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-19 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-20 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-21 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-22 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-23 | $-8.94 | $36,066,667 | 2 / 3 |
| 2026-10-24 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-25 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-26 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-27 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-28 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-29 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-30 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-10-31 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-11-01 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-11-02 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-11-03 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-11-04 | $-8.94 | $36,066,667 | 2 / 2 |
| 2026-11-05 | $-8.94 | $36,066,667 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.